Fahd Al-Saghir is a Nephrology physician. OpenAlex indexes 14 publications with 243 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
44200 Woodward Ave
Suite 209
Pontiac, MI 483415045
Telephone
248-253-0330Registry record last updated 9 Dec 2009.
Industry payments
34 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Biogen, Inc.Program year202513 payments
- Novo Nordisk IncProgram year20252 payments
- Ardelyx, Inc.Program year20257 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
49.1%Angiotensin receptor blocker (ARB)9.4%Losartan Potassium80%Losartan-Hydrochlorothiazide20%Part D<11 patientsLoop diuretic7.8%Furosemide100%Part D≥27 patients+ 6 more classes in this area
Nervous system
27.5%Benzodiazepine17.5%Midazolam hydrochloride100%Part B, office-administered≥106 patientsOpioid Agonist9.1%Fentanyl citrate100%Part B, office-administered≥81 patients+ 1 more class in this area
Metabolism & gastrointestinal
17.7%SGLT2 inhibitor7.7%Farxiga56%Jardiance44%Part D≥12 patientsVitamin D3 Analog4%Calcitriol100%Part D≥19 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Unraveling the Hidden Impact: A Case Report on Enzalutamide-Induced Electrolyte Abnormalities
Journal of the American Society of Nephrology
2025 - Predictors of In-Hospital Mortality and 90-Day Kidney Outcomes in Hospitalized Adults with Sickle Cell Disease and AKI: A Multicenter Retrospective Study
Journal of the American Society of Nephrology
2025 - Dealing with dramatic health care problems during times of natural disaster and armed conflict
Kidney International
2023 - End-Stage Kidney Disease in Areas of Armed Conflicts: Challenges and Solutions
Seminars in Nephrology
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”